



March 27, 2017

## Dicerna Pharmaceuticals to Present at the BioCentury 24th Annual Future Leaders in the Biotech Industry Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present a corporate update at the BioCentury 24<sup>th</sup> Annual Future Leaders in the Biotech Industry Conference on Friday, April 7, 2017, at 3:00 p.m. ET. The conference will be held at the Millennium Broadway Hotel & Conference Center in New York City.

Management will be available for one-on-one meetings with conference attendees. To schedule a meeting, contact Paula Schwartz, managing director, Rx Communications Group, LLC at [pschwartz@rxir.com](mailto:pschwartz@rxir.com).

### About Dicerna Pharmaceuticals, Inc.

Dicerna Pharmaceuticals, Inc., is a biopharmaceutical company focused on the discovery and development of innovative RNAi-based therapeutics for diseases involving the liver, including rare diseases, chronic liver diseases, cardiovascular diseases, and viral infectious diseases. The Company is leveraging its proprietary GalXC<sup>TM</sup> RNAi technology platform to build a broad pipeline in these core therapeutic areas, focusing on target genes where connections between target gene and diseases are well understood and documented. The Company intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners. For more information, please visit [www.dicerna.com](http://www.dicerna.com).

View source version on [businesswire.com](http://www.businesswire.com): <http://www.businesswire.com/news/home/20170327005985/en/>

### Investor:

Rx Communications Group  
Paula Schwartz, 917-322-2216  
[pschwartz@rxir.com](mailto:pschwartz@rxir.com)

or

### Media :

SmithSolve  
Alex Van Rees, 973-442-1555 ext. 111  
[alex.vanrees@smithsolve.com](mailto:alex.vanrees@smithsolve.com)

Source: Dicerna Pharmaceuticals, Inc.

News Provided by Acquire Media